PSI Advisors’s ImmunityBio IBRX Stock Holding History

PSI Advisors’s Portfolio IBRX Stock Details IBRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-350	Closed	-$2.21K	–	902
2024 Q2	$2.21K	Hold	350	–	–	﹤0.01%	708
2024 Q1	$1.88K	Hold	350	–	–	﹤0.01%	666
2023 Q4	$1.76K	Hold	350	–	–	﹤0.01%	725
2023 Q3	$592	Hold	350	–	–	﹤0.01%	768
2023 Q2	$973	Hold	350	–	–	﹤0.01%	727
2023 Q1	$637	Hold	350	–	–	﹤0.01%	704
2022 Q4	$1.77K	Hold	350	–	–	﹤0.01%	616
2022 Q3	$2K	Hold	350	–	–	﹤0.01%	622
2022 Q2	$1K	Hold	350	–	–	﹤0.01%	722
2022 Q1	$2K	Hold	350	–	–	﹤0.01%	625
2021 Q4	$2K	Hold	350	–	–	﹤0.01%	668
2021 Q3	$3K	Buy	+350	New	+$3.85K	﹤0.01%	628

Other funds holding IBRX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

PSI Advisors's IBRX Position: Q3 2024 in Review

PSI Advisors sold out of ImmunityBio (IBRX) in Q3 2024, closing a stake of 350 shares — an estimated $2.21K sold.

PSI Advisors first reported a position in IBRX in Q3 2021 and held it in 12 quarters. The position peaked at $3K in Q3 2021. 181 funds tracked by Wall St. Rank hold IBRX as of Q3 2024.

PSI Advisors reported no remaining ImmunityBio position as of Q3 2024 after selling out during the quarter.
PSI Advisors sold 350 ImmunityBio shares in Q3 2024, an estimated $2.21K.
PSI Advisors first reported a position in ImmunityBio in Q3 2021 and held it in 12 quarters.
PSI Advisors's ImmunityBio position peaked at $3K in Q3 2021.
181 funds tracked by Wall St. Rank held ImmunityBio as of Q3 2024.

Based on PSI Advisors's 13F filing for Q3 2024, filed 22 Oct 2024.